Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

NCT03305016 is registered in ClinicalTrials.gov with Ascendis Pharma Endocrinology Division A/S as lead sponsor.

NCT NCT03305016
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03305016 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Phase
Phase 3
Overall status
Completed
Start date
November 13, 2017
Completion date
March 19, 2019
Enrollment
146 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, growth hormone deficiency, pediatric, hormone deficiency, pituitary diseases